Product Description
FLI1 Antibody [FLVI1-1] | 34-039 | ProSci
Host: Mouse
Reactivity: Human
Homology: N/A
Immunogen: Human partial recombinant protein (amino acids 107-216) was used as the immunogen for this FLI1 antibody.
Research Area: Cell Cycle, Obesity
Tested Application: WB, Flow, IF
Application: Western blot: 1-2 ug/m;l
Flow Cytometry: 0.5-1ug/10^6 cells
IF: 1-2 ug/ml
The concentration stated for each application is a general starting point. Variations in protocols, secondaries and substrates may require the FLI1 antibody to be titered up or down for optimal performance.
Specificiy: N/A
Positive Control 1: N/A
Positive Control 2: N/A
Positive Control 3: N/A
Positive Control 4: N/A
Positive Control 5: N/A
Positive Control 6: N/A
Molecular Weight: N/A
Validation: N/A
Isoform: N/A
Purification: Protein G affinity chromatography
Clonality: Monoclonal
Clone: FLVI1-1
Isotype: IgG
Conjugate: Unconjugated
Physical State: Liquid
Buffer: PBS with 0.1 mg/ml BSA and 0.05% sodium azide
Concentration: 0.2 mg/mL
Storage Condition: Aliquot and Store at 2-8˚C. Avoid freez-thaw cycles.
Alternate Name: Friend leukemia integration 1 transcription factor, Proto-oncogene Fli-1, Transcription factor ERGB, FLI1
User Note: Optimal dilutions for each application to be determined by the researcher
BACKGROUND: Friend leukemia integration 1 is a member of the ETS family of DNA binding transcription factors that is involved in cellular proliferation and tumorigenesis. Members of the Ets gene family share a highly conserved carboxy-terminal domain containing a sequence related to the SV40 large T antigen nuclear localization signal sequence. Approximately 90% of Ewing's Sarcoma (EWS) / Primitive Neuroectodermal Tumors (PNET) have a specific translocation, t (11;22) (q24;q12) , which results in fusion of EWS to Fli-1, and production of an EWS-Fli-1 fusion protein. Among normal tissues only endothelial cells and small lymphocytes express Fli-1. This protein is expressed in majority of vascular tumors including angiosarcomas, hemangioendotheliomas, hemangiomas, and Kaposi's Sarcomas. High sensitivity and specificity of Fli-1 equals to or exceeds that of the established vascular markers like CD31, CD34, and Factor VIII.